🧪Change in Scientific Review Panel Meeting Notice – NIH April 2025
The National Institutes of Health announces an amended notice for the Center for Scientific Review Special Emphasis Panel meeting on brain and neural injury scheduled for May 6, 2025. The update includes a change in the contact person and confirms that the meeting will remain closed to the public.
Learn More📅Notice of Public Meeting
Notice is hereby given, pursuant to the provisions of the rules and regulations of the U.S. Commission on Civil Rights (Commission) and the Federal Advisory Committee Act, that the Montana Advisory Committee (Committee) to the U.S. Commission on Civil Rights will hold a public business meeting via Zoom at 3 p.m. MT on Wednesday, May 21, 2025.
Learn More🔍Correction Notice on PBGC Asset Allocation Regulation
This document provides a correction to a prior publication regarding the allocation of assets in single-employer plans by the Pension Benefit Guaranty Corporation. It specifically addresses an editorial error in the supplementary information section of the rule, ensuring clarity in the regulatory text related to benefit valuation assumptions.
Learn More📅Notice of Public Meeting for Rhode Island Advisory Committee
Notice is hereby given, pursuant to the provisions of the rules and regulations of the U.S. Commission on Civil Rights (Commission) and the Federal Advisory Committee Act, that the Rhode Island Advisory Committee (Committee) to the U.S. Commission on Civil Rights will a public meeting via Zoom. The purpose is for the committee to meet as a newly appointed committee.
Learn More📅Notice of Change in National Science Foundation Meeting Schedule
The National Science Foundation has announced a change in the scheduling of its upcoming Sunshine Act meeting, originally set for April 1, 2025. The meeting is now rescheduled to April 9, 2025. For further inquiries, Chris Blair is the designated point of contact.
Learn More🗓️Federal Election Commission Sunshine Act Meeting Notice
The Federal Election Commission announces a meeting under the Sunshine Act, detailing the previously scheduled time and discussing additional items, including a draft advisory opinion related to the Government Accountability Institute. This notice is aimed at informing the public and stakeholders about the upcoming meeting and its agenda.
Learn More📢Public Briefing Notice for Guam Advisory Committee on Civil Rights
Notice is hereby given, pursuant to the provisions of the rules and regulations of the U.S. Commission on Civil Rights (Commission) and the Federal Advisory Committee Act, that the Guam Advisory Committee (Committee) to the U.S. Commission on Civil Rights will hold a virtual, public briefing via Zoom at 9:30 a.m. ChST on Thursday, April 10, 2025 (7:30 p.m. ET on Wednesday, April 9, 2025). The purpose of this briefing is to hear testimony on the topic, Overrepresentation of FAS Members in the Criminal Justice System on Guam.
Learn More📅Cancellation Notice of National Institute on Drug Abuse Meeting
The Department of Health and Human Services has officially canceled the scheduled meeting for the National Institute on Drug Abuse Special Emphasis Panel. No rescheduling will occur, and the cancellation notice follows a previously published announcement. The meeting was set to take place in April 2025 at the NIH headquarters in Bethesda, MD.
Learn More🗣️Notice of Louisiana Advisory Committee Public Meeting on Mental Health
Notice is hereby given, pursuant to the provisions of the rules and regulations of the U.S. Commission on Civil Rights (Commission) and the Federal Advisory Committee Act, that the Louisiana Advisory Committee (Committee) to the U.S. Commission on Civil Rights will hold a public meetings via Zoom. The purpose of this meeting is for the Committee to review and discuss a project proposal regarding involuntary mental health commitments in Louisiana.
Learn More⚖️Restek Corporation's Import Application for Controlled Substances Notice
Restek Corporation has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information.
Learn More